NKF KDOQI GUIDELINES

KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Children With Chronic Kidney Disease

Guideline 1: Evaluation of Calcium and Phosphorus Metabolism
Guideline 2: Assessment of Bone Disease Associated with CKDM
Guideline 3: Surgical Management of Osteodystrophy
Guideline 4: Target Serum Phosphorus Levels
Guideline 5: Management of Dietary Phosphorus Intake in Children with CKD
Guideline 6: Use of Phosphate Binders in CKD
Guideline 7: Serum Calcium and Calcium-Phosphorus Product
Guideline 8: Prevention and Treatment of Vitamin D Insufficiency and Vitamin D Deficiency in CKD Patients
Guideline 9: Active Vitamin D Therapy in CKD Patients
- Guideline 9A: Active Vitamin D Therapy in CKD Patients with CKD Stages 2-4
- Guideline 9B: Active Vitamin D Therapy in Patients on Dialysis (CKD Stage 5)
Guideline 10: Dialysate Calcium Concentrations
Guideline 11: Recommendations for the Use of Growth Hormone for Children with CKD
Guideline 12: Aluminum Overload and Toxicity in CKD
Guideline 13: Treatment of Aluminum Toxicity
Guideline 14: Treatment of Bone Disease in CKD
- Guideline 14A: Hyperparathyroid (High-Turnover) Bone Disease
- Guideline 14B: Rickets/Osteomalacia
- Guideline 14C: Adynamic Bone Disease
Guideline 15: Parathyroidectomy in Patients with CKD
Guideline 16: Metabolic Acidosis
Guideline 17: Bone Disease in the Pediatric Kidney Transplant Recipient